Review



rabbit polyclonal antisera against alpase  (Cusabio)


Bioz Verified Symbol Cusabio is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 92
      Buy from Supplier

    Structured Review

    Cusabio rabbit polyclonal antisera against alpase
    Fig. 3. ABL increases bone formation without excessive enhancement of bone resorption at the vertebral defect site. (A) Representative images of Hematoxylin- Eosin–stained defected vertebrae after administration. Upper half; overall view, scale bar = 500 μm. Lower half; magnified view, scale bar = 50 μm. (B and C) Representative images of defected vertebrae with immunostaining of <t>ALPase,</t> PHOSPHO1, CatK, and ALPase/PCNA after (B) vehicle or (C) ABL administration. Arrows indicate ALPase/PCNA double-positive preosteoblasts. Scale bar = 50 μm. (D and E) Time-course changes in (D) ALP+Ar/T.Ar and (E) PHOSPHO1+Ar/T.Ar at the vertebral defect site (n = 6 at all timepoints). (F) Time-course changes in N.Oc/BS at the vertebral defect site (n = 6 except for OVX Vehicle With Defect at Week 2 [n = 5]). *P < 0.05, OVX ABL With Defect vs. OVX Vehicle With Defect, †P < 0.05, OVX Vehicle With Defect vs. OVX Vehicle, Tukey’s test.
    Rabbit Polyclonal Antisera Against Alpase, supplied by Cusabio, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rabbit+polyclonal+antisera+against+alpase/Rabbit+anti-+Rabbit+Polyclonal+Antibody/pm38402920-77-11-29
    Average 92 stars, based on 1 article reviews
    rabbit polyclonal antisera against alpase - by Bioz Stars, 2026-09
    92/100 stars

    Images

    1) Product Images from "Abaloparatide promotes bone repair of vertebral defects in ovariectomized rats by increasing bone formation."

    Article Title: Abaloparatide promotes bone repair of vertebral defects in ovariectomized rats by increasing bone formation.

    Journal: Bone

    doi: 10.1016/j.bone.2024.117056

    Fig. 3. ABL increases bone formation without excessive enhancement of bone resorption at the vertebral defect site. (A) Representative images of Hematoxylin- Eosin–stained defected vertebrae after administration. Upper half; overall view, scale bar = 500 μm. Lower half; magnified view, scale bar = 50 μm. (B and C) Representative images of defected vertebrae with immunostaining of ALPase, PHOSPHO1, CatK, and ALPase/PCNA after (B) vehicle or (C) ABL administration. Arrows indicate ALPase/PCNA double-positive preosteoblasts. Scale bar = 50 μm. (D and E) Time-course changes in (D) ALP+Ar/T.Ar and (E) PHOSPHO1+Ar/T.Ar at the vertebral defect site (n = 6 at all timepoints). (F) Time-course changes in N.Oc/BS at the vertebral defect site (n = 6 except for OVX Vehicle With Defect at Week 2 [n = 5]). *P < 0.05, OVX ABL With Defect vs. OVX Vehicle With Defect, †P < 0.05, OVX Vehicle With Defect vs. OVX Vehicle, Tukey’s test.
    Figure Legend Snippet: Fig. 3. ABL increases bone formation without excessive enhancement of bone resorption at the vertebral defect site. (A) Representative images of Hematoxylin- Eosin–stained defected vertebrae after administration. Upper half; overall view, scale bar = 500 μm. Lower half; magnified view, scale bar = 50 μm. (B and C) Representative images of defected vertebrae with immunostaining of ALPase, PHOSPHO1, CatK, and ALPase/PCNA after (B) vehicle or (C) ABL administration. Arrows indicate ALPase/PCNA double-positive preosteoblasts. Scale bar = 50 μm. (D and E) Time-course changes in (D) ALP+Ar/T.Ar and (E) PHOSPHO1+Ar/T.Ar at the vertebral defect site (n = 6 at all timepoints). (F) Time-course changes in N.Oc/BS at the vertebral defect site (n = 6 except for OVX Vehicle With Defect at Week 2 [n = 5]). *P < 0.05, OVX ABL With Defect vs. OVX Vehicle With Defect, †P < 0.05, OVX Vehicle With Defect vs. OVX Vehicle, Tukey’s test.

    Techniques Used: Staining, Immunostaining

    Related Articles

    Incubation:

    Article Title: Abaloparatide promotes bone repair of vertebral defects in ovariectomized rats by increasing bone formation.
    Article Snippet: In brief, after inhibition of endogenous peroxidases, dewaxed paraffin sections were pretreated with 1 % bovine serum albumin (BSA; Serologicals Proteins Inc., Kankakee, IL, USA) in PBS (1 % BSA-PBS) for 30 min. .. Sections were then incubated for 2–3 h at room temperature with rabbit polyclonal antisera against ALPase diluted 1:200 in 1 % BSA-PBS [22], rabbit polyclonal anti-PHOSPHO1 antibody (No. Q8TCT1, Cusabio Technology LLC, Houston, TX, USA) diluted 1:200, and mouse monoclonal anti-CatK antibody (No. F-95, Daiichi Fine Chemical Co., Ltd., Takaoka, Japan) diluted 1:100, followed by incubation with horseradish peroxidase (HRP)-conjugated anti-rabbit IgG (No. ab6112, Abcam plc., Cambridge, Cambridgeshire, UK) diluted 1:100 in 1 % BSA-PBS or HRP-conjugated anti-mouse IgG (No. 61-6520, Chemicon International Inc., Temecula, CA, USA) diluted 1:100. ..



    Similar Products

    rabbit polyclonal antisera against alpase  (Cusabio)
    92
    Cusabio rabbit polyclonal antisera against alpase
    Fig. 3. ABL increases bone formation without excessive enhancement of bone resorption at the vertebral defect site. (A) Representative images of Hematoxylin- Eosin–stained defected vertebrae after administration. Upper half; overall view, scale bar = 500 μm. Lower half; magnified view, scale bar = 50 μm. (B and C) Representative images of defected vertebrae with immunostaining of <t>ALPase,</t> PHOSPHO1, CatK, and ALPase/PCNA after (B) vehicle or (C) ABL administration. Arrows indicate ALPase/PCNA double-positive preosteoblasts. Scale bar = 50 μm. (D and E) Time-course changes in (D) ALP+Ar/T.Ar and (E) PHOSPHO1+Ar/T.Ar at the vertebral defect site (n = 6 at all timepoints). (F) Time-course changes in N.Oc/BS at the vertebral defect site (n = 6 except for OVX Vehicle With Defect at Week 2 [n = 5]). *P < 0.05, OVX ABL With Defect vs. OVX Vehicle With Defect, †P < 0.05, OVX Vehicle With Defect vs. OVX Vehicle, Tukey’s test.
    Rabbit Polyclonal Antisera Against Alpase, supplied by Cusabio, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rabbit+polyclonal+antisera+against+alpase/Rabbit+anti-+Rabbit+Polyclonal+Antibody/pm38402920-77-11-29
    Average 92 stars, based on 1 article reviews
    rabbit polyclonal antisera against alpase - by Bioz Stars, 2026-09
    92/100 stars
    		  Buy from Supplier

    Image Search Results


    Fig. 3. ABL increases bone formation without excessive enhancement of bone resorption at the vertebral defect site. (A) Representative images of Hematoxylin- Eosin–stained defected vertebrae after administration. Upper half; overall view, scale bar = 500 μm. Lower half; magnified view, scale bar = 50 μm. (B and C) Representative images of defected vertebrae with immunostaining of ALPase, PHOSPHO1, CatK, and ALPase/PCNA after (B) vehicle or (C) ABL administration. Arrows indicate ALPase/PCNA double-positive preosteoblasts. Scale bar = 50 μm. (D and E) Time-course changes in (D) ALP+Ar/T.Ar and (E) PHOSPHO1+Ar/T.Ar at the vertebral defect site (n = 6 at all timepoints). (F) Time-course changes in N.Oc/BS at the vertebral defect site (n = 6 except for OVX Vehicle With Defect at Week 2 [n = 5]). *P < 0.05, OVX ABL With Defect vs. OVX Vehicle With Defect, †P < 0.05, OVX Vehicle With Defect vs. OVX Vehicle, Tukey’s test.

    Journal: Bone

    Article Title: Abaloparatide promotes bone repair of vertebral defects in ovariectomized rats by increasing bone formation.

    doi: 10.1016/j.bone.2024.117056

    Figure Lengend Snippet: Fig. 3. ABL increases bone formation without excessive enhancement of bone resorption at the vertebral defect site. (A) Representative images of Hematoxylin- Eosin–stained defected vertebrae after administration. Upper half; overall view, scale bar = 500 μm. Lower half; magnified view, scale bar = 50 μm. (B and C) Representative images of defected vertebrae with immunostaining of ALPase, PHOSPHO1, CatK, and ALPase/PCNA after (B) vehicle or (C) ABL administration. Arrows indicate ALPase/PCNA double-positive preosteoblasts. Scale bar = 50 μm. (D and E) Time-course changes in (D) ALP+Ar/T.Ar and (E) PHOSPHO1+Ar/T.Ar at the vertebral defect site (n = 6 at all timepoints). (F) Time-course changes in N.Oc/BS at the vertebral defect site (n = 6 except for OVX Vehicle With Defect at Week 2 [n = 5]). *P < 0.05, OVX ABL With Defect vs. OVX Vehicle With Defect, †P < 0.05, OVX Vehicle With Defect vs. OVX Vehicle, Tukey’s test.

    Article Snippet: Sections were then incubated for 2–3 h at room temperature with rabbit polyclonal antisera against ALPase diluted 1:200 in 1 % BSA-PBS [22], rabbit polyclonal anti-PHOSPHO1 antibody (No. Q8TCT1, Cusabio Technology LLC, Houston, TX, USA) diluted 1:200, and mouse monoclonal anti-CatK antibody (No. F-95, Daiichi Fine Chemical Co., Ltd., Takaoka, Japan) diluted 1:100, followed by incubation with horseradish peroxidase (HRP)-conjugated anti-rabbit IgG (No. ab6112, Abcam plc., Cambridge, Cambridgeshire, UK) diluted 1:100 in 1 % BSA-PBS or HRP-conjugated anti-mouse IgG (No. 61-6520, Chemicon International Inc., Temecula, CA, USA) diluted 1:100.

    Techniques: Staining, Immunostaining